Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Using Index Level To Forecast Direction offers a structured method to translate index signals into actionable forecasts.
18,459 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Solana looks poised at a crossroads as derivatives data shows a long-dominant tilt without fresh capital. The solana ...
Florida’s housing to-do list in 2026 features divergent markets, tighter loan conditions, and price concessions as bu...
Bitcoin hovers around 82,000 as traders assess whether the bear market bottom when will be confirmed. A sustained ETF...
Griffon (GFF) 2026 earnings season offers clues about growth and margins across its portfolio. This guide breaks down...
U.S. credit card debt climbed to a record $1.28 trillion in late 2025, even as a booming influencer economy promotes ...
Poppi’s journey shows how founders turn personal risk into billion-dollar exits. The cofounder maxed credit and even ...
Bitcoin surged toward a crucial resistance level as news spread that trump just flew china and a tech-heavy delegatio...
Lucid stock sits near $7, tempting bargain hunters. This article breaks down the real risks, the potential catalysts,...
As automation advances, hospitality leaders argue that Gen Z workers want ai-proof jobs with purpose. A 50-property c...
Hyperliquid's HYPE defies a broad crypto slip, trading above $45 as Maxi Doge nears a $5 million presale milestone. T...
Bitcoin is trading in a lower gear as institutional demand wanes and macro pressures mount. ETF outflows and tepid on...